Claims for Patent: 7,829,297
✉ Email this page to a colleague
Summary for Patent: 7,829,297
Title: | Treatment of cancers expressing p95 ErbB2 |
Abstract: | The truncated ErbB2 receptor (p95.sup.ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95.sup.ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95.sup.ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95.sup.ErbB2 inhibitor, and methods of treating such patients. |
Inventor(s): | Spector; Neil Lee (Durham, NC), Xia; Wenle (Durham, NC) |
Assignee: | GlaxoSmithKline LLC (Philadelphia, PA) |
Application Number: | 12/366,457 |
Patent Claims: | 1. A method of selecting therapy for a human subject having a solid epithelial tumor that overexpresses ErbB2, said method comprising: (a) determining whether said
solid epithelial tumor expresses p95.sup.ErbB2; (b) if said solid epithelial tumor is determined in step (a) to express p95.sup.ErbB2, selecting a therapy that includes the administration of GW572016 for said human subject.
2. A method according to claim 1 where the expression of p95.sup.ErbB2 in tumor tissue is determined by immunohistochemical methods. 3. A method according to claim 1 where expression of p95.sup.ErbB2 is determined by measuring ErbB2 extracellular domain in a sample of the subject's serum. 4. A method according to claim 1 where said tumor is selected from breast, ovarian, colon, head and neck, bladder, renal cell and lung tumors. 5. A method according to claim 4 where said solid epithelial tumor is a breast tumor. 6. A method according to claim 1 where said subject has previously been treated with trastuzumab. 7. A method of selecting therapy for a human subject having a solid epithelial tumor that overexpresses ErbB2, said method comprising: (a) measuring the serum level of ErbB2 ECD of the subject to determine if said ECD level is elevated; (b) selecting a therapy that includes the administration of GW572016 for said human subject if said ECD level is elevated. 8. A method of selecting therapy for a human subject having a solid epithelial tumor that overexpresses ErbB2, said method comprising: (a) measuring p95.sup.ErbB2 levels is samples of said solid epithelial tumor to determine if p95.sup.ErbB2 overexpressed; (b) selecting a therapy that includes the administration of GW572016 for said human subject if p95.sup.ErbB2 is overexpressed. |
Details for Patent 7,829,297
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2023-08-01 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2023-08-01 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2023-08-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.